This website uses cookies to enhance the user experience.
||
NORGESPLASTER AS

NORGESPLASTER AS995 011 727

Process industry
Limited company
Granlivegen 21 4707 VENNESLA, Norge

NORGESPLASTER AS

Operating
startsida - norgesplaster.no
Velkommen til Norgesplaster - Sår og skadebehandling siden 1938
Fremstilling, forskning og utvikling av, samt handel, herunder import og eksport, av farmasøytiske, medisinske og andre kjemiske produkter, samt andre produkter for behandling og forebygging av sykdommer, samt alt hva hermed står i forbindelse, herunder deltagelse i andre virksomheter.
Produksjon av farmasøytiske preparater.

Keywords

productionpharmaceuticalsantiserablood fractionsvaccineshomeopathic preparationscontraceptive productsbone buildingdiagnostic preparationspregnancy testsbiotechnological medicinescotton woolgasbandagesdressings

Links

Organization

Chairman of the board
Years since formation
16 years
since Jan 16, 2010
Type
Limited company
VAT registered
Yes
Number of employees
54

Ownership

Number of shares and share classes
8,000,000
1 share class
Total number of shareholders
1
person

Financials

Total operating income 2025
211,184,925
NOK
Annual total result 2025
8,139,635
NOK
Total equity 2025
23,186,521
NOK
Last update: Jul 11, 2026

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Chairman-
Board Member-
Board Member-
Board Member-
Alternate Member-
Alternate Member-
Board Member-
Alternate Member-

Others

NameRoleShares
E
ERNST & YOUNG AS
Auditor-
L
LUNDEN REGNSKAP AS
Accountant-
Last update: Jun 22, 2026

Ownership

Company shareholders

NameShare classTotal number of sharesShare
Ordinary shares
8,000,000
100 %
Last update: Jun 2, 2025

Financials

in NOK

Summary

Year20252024202320222021
Total operating income
211,184,925
207,203,693
178,968,675
192,806,572
190,450,352
Annual Total Result
8,139,635
12,856,919
4,920,938
9,642,314
13,355,035
Total assets
110,387,103
109,991,981
83,800,883
93,155,323
89,264,872
Total liabilities
87,200,584
92,059,096
65,301,917
74,725,884
71,180,893
Total equity
23,186,521
17,932,886
18,498,966
18,429,439
18,083,978

P&L

Year20252024202320222021
Total operating income
211,184,925
207,203,693
178,968,675
192,806,572
190,450,352
Total operating costs
198,841,522
188,698,140
171,028,623
180,622,630
172,292,477
Operating result
12,343,403
18,505,553
7,940,052
12,183,943
18,157,875
Financial income/costs
-1,897,357
-2,005,548
-1,617,362
181,520
-530,245
Profit before tax
10,446,046
16,500,005
6,322,690
12,365,462
17,627,631
Total tax & extraordinary income/cost
2,306,411
3,643,086
1,401,752
2,723,148
4,272,596
Annual Total Result
8,139,635
12,856,919
4,920,938
9,642,314
13,355,035

Balance overview

Year20252024202320222021
Total fixed assets
13,602,307
11,972,823
11,303,306
10,723,079
11,893,550
Total current assets
96,784,796
98,019,158
72,497,576
82,432,243
77,371,321
Total assets
110,387,103
109,991,981
83,800,883
93,155,323
89,264,872
Short term debt
30,155,020
50,515,793
29,583,504
46,520,118
65,748,758
Long term debt
0
41,543,303
35,718,413
28,205,766
5,432,135
Total liabilities
87,200,584
92,059,096
65,301,917
74,725,884
71,180,893
Contributed capital
17,358,493
17,358,493
17,358,493
17,358,493
17,358,493
Retained earnings
5,828,027
574,392
1,140,473
1,070,945
725,485
Total equity
23,186,521
17,932,886
18,498,966
18,429,439
18,083,978
Total equity and liabilities
110,387,104
109,991,982
83,800,883
93,155,323
89,264,872

Classification

21st company classification
BETA
Industrial large enterprise
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
C
Main industrial area
Manufacturing
21
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.2
Main industrial group
Manufacture of pharmaceutical preparations
21.20
Industrial group
Manufacture of pharmaceutical preparations
21.200
Industrial group
Manufacture of pharmaceutical preparations